Oric Pharmaceuticals, Inc.
ORIC Pharmaceuticals (Nasdaq: ORIC) is a clinical-stage biopharmaceutical company developing cancer therapies intended to address mechanisms of treatment resistance. Its two lead clinical candidates are rinzimetostat, an allosteric inhibitor of PRC2 being studied for advanced prostate cancer, and enozertinib, an oral,… From the company’s description.
In fiscal 2025, Oric Pharmaceuticals, Inc. reported a net loss of $129.47M. Operations used $110.97M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Oric Pharmaceuticals, Inc. does
In the company’s own words
ORIC Pharmaceuticals (Nasdaq: ORIC) is a clinical-stage biopharmaceutical company developing cancer therapies intended to address mechanisms of treatment resistance. Its two lead clinical candidates are rinzimetostat, an allosteric inhibitor of PRC2 being studied for advanced prostate cancer, and enozertinib, an oral, brain-penetrant inhibitor of EGFR exon 20 and atypical mutations being studied for non-small cell lung cancer. Development includes combination trials of rinzimetostat with the androgen-receptor inhibitors apalutamide and darolutamide, and trials of enozertinib alone and with other therapies. The company applies a precision-oncology approach, using biomarkers to assess targets and pathways and support patient selection. Its programs address hormone-dependent cancers, genetically defined tumors and other cancer dependencies; it has prioritized resources on its two lead clinical programs and substantially reduced preclinical discovery work. ORIC reported 104 full-time employees as of December 31, 2025.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1796280
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Oric Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Oric Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Oric Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Oric Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Oric Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”